Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	48.57B
Revenue (ttm)	7.53B
Net Income (ttm)	1.06B
Shares Out	n/a
EPS (ttm)	1.23
PE Ratio	45.74
Forward PE	n/a
Dividend	0.62 (1.84%)
Ex-Dividend Date	Jun 7, 2024

Volume	3,138,963
Average Volume	5,751,958
Open	33.90
Previous Close	33.85
Day's Range	32.85 - 35.45
52-Week Range	24.50 - 58.80
Beta	0.91
RSI	54.57
Earnings Date	Mar 28, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2023, HKG:3347's revenue was 7.38 billion, an increase of 4.21% compared to the previous year's 7.09 billion. Earnings were 2.02 billion, an increase of 0.91%.

Financial numbers in CNY